afatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
pharma
Boehringer Ingelheim Pty
Boehringer Ingelheim Pty Ltd
Boehringer Ingelheim Pty drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
North Ryde, AU HQ
TGA registrant Type
Company details
- Status
- Public
- HQ
- North Ryde, AU
- Programs
- 0
- Drugs
- 8
- Patents
- 2
Boehringer Ingelheim Pty pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Boehringer Ingelheim Pty drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
empagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
Development asset linked to Boehringer Ingelheim Pty in public FDA and regional records.
-
Development asset linked to Boehringer Ingelheim Pty in public FDA and regional records.
-
linagliptin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.
- Target
- Dipeptidyl peptidase 4
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
Development asset linked to Boehringer Ingelheim Pty in public FDA and regional records.
-
nintedanib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to Boehringer Ingelheim Pty in public FDA and regional records.